Related Experiment Video
Updated: Nov 6, 2025
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
5.5K
P2Y12 inhibitors for the neurointerventionalist
Robin J Borchert1, Davide Simonato2,3, Charlotte R Hickman4
1Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Summary
Antiplatelet use in neurointerventional procedures lacks standardized protocols. This review clarifies P2Y12 inhibitor characteristics and risks, essential for growing endovascular treatments.
Area of Science:
- Neuroendovascular procedures
- Pharmacology
- Clinical practice guidelines
Background:
- Antiplatelet agents are crucial in neurointerventional procedures.
- Current protocols for their use are scarce and inconsistent.
- Diverse antiplatelet agents present challenges regarding administration, efficacy, and complications.
Purpose of the Study:
- To review the literature on P2Y12 inhibitors in neurointerventional procedures.
- To assess the quality of existing evidence.
- To identify research gaps in this field.
Main Methods:
- Systematic literature review.
- Analysis of P2Y12 inhibitor properties (route, dose, onset, efficacy).
- Evaluation of ischemic and hemorrhagic complication data.
Main Results:
- Summarizes current evidence on P2Y12 inhibitor use in neurointervention.
- Highlights variability in clinical practice and agent characteristics.
- Identifies a need for more robust clinical trials.
Conclusions:
- Standardized antiplatelet protocols are needed for neurointerventional procedures.
- Further research is essential to optimize P2Y12 inhibitor selection and management.
- Evidence quality needs improvement to guide clinical decision-making.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
808
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
808
01:29Venous Thrombosis III: Interprofessional Care
89
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
89
01:27Peripheral Artery Disease III: Interprofessional Care
93
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
93
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.5K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
304
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
304
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.2K